Keywords
Neisseria meningitidis, vaccination, health impact assessment, scoping review
Neisseria meningitidis, vaccination, health impact assessment, scoping review
Neisseria meningitidis is a Gram-negative bacterium that is found in the mucous membrane of the nasopharynx and tonsils of about 10% of the human population1. Most N. meningitidis strains are harmless, but some encapsulated clones are virulent and can cause meningococcaemia, meningitis, and septic shock1. Historically, the highest incidence of meningococcal disease has been described in sub-Saharan Africa, in the so-called African meningitis belt, which stretches from the west of Senegal to the east of Ethiopia2. In this region, endemic rates are high, and large-scale epidemics have occurred every 8–12 years for more than a century, typically in dry seasons1–4. The number of cases of meningococcal meningitis reported from the African meningitis belt is around 30,000 per year4.
There are at least 13 serogroups of N. meningitidis (A, B, C, D, E, H, I, K, L, W135, X, Y, and Z) that are classified based on differences in capsule polysaccharides1. Serogroup A used to be the main causative agent of epidemics in Africa, but massive vaccination campaigns are changing the epidemiology3,5. Validated and licensed conjugate vaccines are available for serogroups A (MenAfriVac®) and C, and there is also a tetravalent vaccine for serogroups A, C, Y, and W1354,6. These vaccines can be used in routine settings (part of routine immunisation scheme) and in response to outbreaks (reactive vaccination)4. Vaccination efforts intensified in 2010 and since then, hundreds of millions of Africans have received a dose of MenAfriVac®3. As a consequence, the incidence of meningococcal meningitis due to serogroup A has decreased, but outbreaks of new clones have been reported3,5.
Our main objective is to evaluate the impact of vaccination on morbidity and mortality due to meningococcal disease in countries of the African meningitis belt. Before engaging in a systematic review, we will assess the size and scope of the body of literature6. The aim at this stage is not to produce a pooled estimate of what the impact of vaccination is, but to evaluate how the authors of the included records have assessed the impact.
The central question of this scoping review is: what is the extent and the nature of the research evidence about the impact of interventions including vaccination against Neisseria meningitidis on the frequency of meningitis in the African meningitis belt? The review question is formulated using the SPICE (setting, perspective, intervention, comparison, evaluation) framework and the key elements are summarised in Table 17.
Records will be included in the review if they meet all the following criteria:
- Reports of primary studies or review articles (not opinion papers); and
- About people living in one of 27 countries corresponding to the African meningitis belt (any population group, any age); and
- Assessing the impact of interventions that include N. meningitidis vaccination; and
- Including an element of comparison (populations with versus without vaccination, or before versus after vaccination); and
- Reporting meningitis frequency. The reported condition can be meningitis due to N. meningitidis, meningitis in general, or death due to meningitis. Disease frequency can be expressed as absolute number of cases, prevalence, or incidence. The denominator can be the general population or a subgroup (e.g. meningitis patients).
Records reporting the impact of mixed interventions (vaccination for N. meningitidis + other interventions such as chemoprophylaxis to prevent meningococcal disease among contacts or vaccination for other pathogens) will be included. If we find a record that reports findings both from countries inside and outside the African meningitis belt, we will include that record and extract only that part of the data that comes from one of the 27 target countries for this review.
A sheet with detailed eligibility criteria will be used for record screening (based on titles and abstracts) and selection (based on full-text papers). A preliminary version of this sheet is available as extended data8. The detailed selection criteria will be pilot-tested on 50 titles and abstracts and refined if necessary.
We will search the following electronic databases: MEDLINE, the Cochrane register of clinical trials, African Index Medicus, and clinicaltrials.gov. Other sources of information will be surveillance reports at country level and online resources of the World Health Organization and other large stakeholders involved in vaccination campaigns (to be identified via the included records). Finally, we also intend to screen the reference lists of included records (especially review papers) and contact experts in the field to check if we have missed any potentially relevant records. There will be no restrictions regarding language, publication date, or study design.
The search strategy is based on the combination of three concepts: the condition of interest, the intervention, and the geographical region (Figure 1). The Boolean operators “AND” and “OR” are used to combine search terms. The planned search syntax for PubMed is given in Table 2. The same general strategy will be used to search the other databases, but small adjustments will be made such as the translation of key words to French, and the adaptation of truncation symbols and parentheses to different search engines.
Data management. Retrieved records will be automatically exported to Microsoft Excel if possible (e.g. from PubMed) and manually added otherwise. All records will get a unique identifier. Information extracted from the included records will be stored in the Excel file. Records that remain after title and abstract screening will also be kept in an EndNote file.
Selection process. Record screening and selection will be done in duplicate by two independent members of the review team (LU and/or GJ and/or NM). Any discordances during screening of titles and abstracts or full-text papers will be solved through discussion with a third member of the review team (KV). For each full-text record that we exclude, the main reason for exclusion will be recorded. The search and selection process will be documented in a PRISMA flowchart9.
Data collection process. Two members of the review team (LU and/or GJ and/or NM) will independently extract the information from the included records using a standard form (preliminary version available as extended data8). This data extraction form will be piloted on at least three full-text records and refined if necessary. The extracted information will first be filled out on the data extraction form (one form per reviewer and per record) and then passed to the Excel file. In case the information is unclear or incomplete, we will describe it as such; we do not intend to contact investigators. Any discordances between the two reviewers will be discussed with a third reviewer (KV).
We will collect information about the record itself and about the study described in the record. Table 3 gives an overview of the data items. The complete preliminary data extraction form is available as extended data8.
Rather than focusing on one or a few specific outcomes, this review focuses on the size and scope of the available research literature and on the nature and extent of the research evidence. The approach will be descriptive; we do not foresee outcome prioritization.
The assessment of risk of bias will be done at study level and independently by two people of our review team. As we are using broad eligibility criteria for this scoping review, we expect to include information in heterogeneous formats and coming from studies following different designs. For randomised trials of interventions, we plan to use the risk-of-bias assessment tool of the Cochrane Collaboration, and for non-randomised studies the ROBINS-I tool. For studies following other designs, we will only describe the study design and the ways impact of vaccination was described and assessed. We plan to describe and discuss the findings of the assessment of risk of bias and will not use them in any other way in data synthesis.
The findings of this review will be presented using figures, tables, and thematic narrative synthesis. Data from the included studies will not be pooled and the synthesis will not lead to recommendations on vaccination for N. meningitidis.
A preliminary structure of the results section is given below, but this may slightly change depending on the content of the included papers:
- Search and selection (with PRISMA flowchart)
- Characteristics of included records: publication type, year, journal, author affiliations
- Study populations: country, setting, size, general population or subgroups
- Interventions: vaccination alone or in combination, rationale, in outbreak, routine or research settings, by government or others
- Vaccines used: type, brand, provider
- Approaches to assess impact: overview of definitions and operationalisation of impact
- Study design: according to the study authors and according to the review team
- Risk of bias assessment
The present review protocol was developed following the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidelines, more specifically the checklist for review protocols (PRISMA-P 2015) and the extension for scoping reviews (PRISMA-ScR 2018)9–11.
The review protocol will be published so that it is publicly available before the actual reviewing activities start. PROSPERO is a specialized platform for review protocols but does not accept scoping reviews. We therefore publish the current protocol on F1000Research, an open access scientific publishing platform. Any changes in the reviewing activities after protocol registration will be listed in the final review paper.
The review team is presented in Table 4.
Name | Affiliation | Role |
---|---|---|
Niurka Molina niurka.molina@ipk.sld.cu | Instituto Pedro Kourí Havana, Cuba | Write draft protocol, search & select studies, extract & synthesise data, write draft review |
Greissi Justiniani gjustiniani@finlay.edu.cu | Instituto Finlay Havana, Cuba | Write draft protocol, search & select studies, extract & synthesise data, write draft review |
Lisset Urquiza lurquiza@finlay.edu.cu | Instituto Finlay Havana, Cuba | Write draft protocol, search & select studies, extract & synthesise data, write draft review |
Maria Eugenia Toledo mariaeugenia@ipk.sld.cu | Instituto Pedro Kourí Havana, Cuba | Provide topic expertise, interpret findings, give feedback on draft texts |
Chukwuemeka Onwuchekwa emyonwuchekwa@gmail.com | Institute of Tropical Medicine, Antwerp, Belgium | Provide context knowledge, give methodological input, give feedback on draft texts |
Kristien Verdonck tverdonck@itg.be | Institute of Tropical Medicine Antwerp, Belgium | Write draft protocol, give methodological input, solve discordances in study selection & data extraction, write draft review, corresponding author |
Ermias Diro ermi_diro@yahoo.com | Gondar University, Gondar, Ethiopia | Provide context knowledge & clinical expertise, give methodological input, give feedback on draft texts |
Nivaldo Linares-Pérez nlinares@finlay.edu.cu | Instituto Finlay Havana, Cuba | Propose topic, provide topic expertise, interpret findings, give feedback on draft texts |
While preparing the present protocol, we tried out preliminary searches to get an idea of the size of the available literature. At the time of submission, formal reviewing activities had not started yet.
Figshare: SupplementaryInformation_Eligibility_DataExtraction. https://doi.org/10.6084/m9.figshare.10078928.v18.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Meningococcal disease, meningococcal genomic epidemiology
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
References
1. Trotter C, Lingani C, Fernandez K, Cooper L, et al.: Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. The Lancet Infectious Diseases. 2017; 17 (8): 867-872 Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, meningococcal disease, research synthesis
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 15 Nov 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)